For US Healthcare Professionals

I am a:

Request a Rep

For US Healthcare Professionals

Prescribing Information

IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)

~8 out of 10 PsO patients continued therapy through 5 years1*

Zoom out icon
Zoom-in icon
Patient retention data chart showing approximately 8 out of 10 patients with plaque psoriasis continued TREMFYA therapy through 5 years
Patient retention data chart showing approximately 8 out of 10 patients with plaque psoriasis continued TREMFYA therapy through 5 years

No conclusions regarding clinical efficacy or safety can be drawn.

*Year 5 represents Week 252.

†Includes patients randomized to TREMFYA® and to placebo at baseline who crossed over to receive TREMFYA® at Week 16.

‡Includes subjects who were randomized but not treated.

§Includes pregnancy, noncompliance with study drug, and/or protocol violation.

Reference: 1. Data on file. Janssen Biotech, Inc.

IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PsO

See results across patient types